February 13, 2017 at 12:23 pm #3197
Brückenkopf recently interviewed with Mr. Dr. Izak Daizade M.D – founder and R&D Manager at UNFO Med, who offers innovative device to treat newborns afflicted with congenital foot deformities.
(Q: Question from Brückenkopf GmbH / A: Answer from Mr. Dr. Izak Daizade M.D by UNFO Med)
Q: Mr. Dr. Daizade, could you please explain which sector is your company specialized in?
A: I am the founder of UNFO Med, and I have more than 35 years of experience in pediatric surgery. UNFO Med. Ltd. is a healthcare company specializing in the orthopedic field, we are a manufacturer of the revolutionary Universal Neonatal Foot Orthotics system.
Q: What are the major markets of your company? Only in Israel or also the international market?
A: We work in the international healthcare market. The UNFO Med system has obtained patent in the United States and China and patent pending status in Brazil, Europe, Canada, Australia, India. Our expert team works very hard to develop new and innovative treatments aimed at bringing relief to thousands of suffering infants afflicted with foot conditions and enable them the happy, pain-free life they so deserve.
Q: Do you have R&D capabilities of your company, or do you co-operate with third parties?
A: UNFO Company has his own R&D capability and cooperates with several Orthopedic Centers world- wide.
Q: Dr., What do you see as challenges and opportunities in the market in 2017?
A: We strongly believe in the importance of providing relief to infants and their families, preventing unnecessary pain and suffering, and bringing aid to those who have been labeled as “incurable.” There is currently no specific treatment for metatarsus adductus (MTA), leading to a certain amount of confusion over when and how to treat MTA in infants. The lack of a specific solution for MTA has left orthopedic centers no choice but to adapt the casting technique indicated for club foot.
This casting technique comes with a number of disadvantages and complications. Due to problematic casting procedure in MTA there have been some understatement and compromising attitude about the treatment indications. More and more newborns in the world enjoy the easy treatment of their foot deformity by UNFO, replacing the old problematic technique of serial casting. There is no doubt that most of complications and surgical interventions can be avoided by adequate treatment in the first months of infant life.
Background: UNFO Med company info